#1ASX ANNOUNCEMENT INVESTOR PRESENTATION FOR EAST-WEST SUMMIT INVION MELBOURNE (AUSTRALIA) 05 March 2024: Invion Limited (ASX: IVX) ("Invion" or the "Company") wishes to release the attached presentation, which will be presented by the Company's Executive Chair and Chief Executive Officer, Thian Chew, at the BioCentury-Bay Helix East-West Summit in Singapore this afternoon. This announcement was approved for release by Thian Chew, Chairman of the Board. Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: [email protected] Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: [email protected] About Invion Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX). About Photodynamic Therapy (PDT) Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs". Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com#2CORPORATE PRESENTATION March 2024 INVION ASX: IVX TM#3DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change. 2#4CLINICAL INFLEXION POINT PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES 3 Clinical stage life-science company using proprietary Photodynamic Therapy (PDT) technology (PhotosoftTM) to treat a range of cancers and infectious diseases. Focus on unmet medical needs particularly in Asian-centric indications that are globally relevant Existing (Peter Mac, Hudson Institute) and future international partnership potential CANCER (INV043) Multiple cancer indications ■ Ablation and activation of immune response Improved efficacy of immune checkpoint inhibitor (ICI) treatments when in combination Topical and systemic formulations Strong therapeutic profile Target Indications ■ Non-melanoma skin cancer (topical) ■ Solid tumour cancer TBD (IV) ■ Anogenital cancer (topical) ■ Additional TBD INFECTIOUS DISEASES ■ Broad spectrum antimicrobial activity ■ No known drug resistance (to address AMR) Commercially viable focus ■ Target Indications ■ Oral antimicrobial: Peri-implant mucositis Human Papilloma Virus (HPV), with Dr.inB ■ Additional TBD Core Australian cancer development fully funded by RMW Cho Group, inventor/owner of Photosoft¹ Expanded Territories in cancer and AID (incl. in Asia Pacific¹, and US/Canada for ID). Invion co-contributes 25% pre-clinical & 75% clinical costs 1 Includes Asia and Oceania (other than Australia and New Zealand, which are covered under a pre-existing distribution and licence agreement with RMW), and excludes the specified territories of China, Macau and Taiwan. The USA and Canada are included for Infectious Disease Indications. INVION#54 BACKGROUND AND DEVELOPMENT TIMEFRAME: CANCER PATHWAY TO CLINICAL TRIALS Partnership with Peter Mac Potential in metastatic cancers Photosoft destroys ovarian cancer in vitro Partnership with Hudson Institute Reverse merger into IVX Discovery/Pre-clinical for IVX-P02/P03 COVID-19 Lockdowns PoC 2: Complete regression of TNBC PoC 1: INV043 effective PoC 3: INV043 significantly improves ICI therapy INV043 effective against anal cancer SCC in vitro HUDSON INSTITUTE OF MEDICAL RESEARCH GMP manufacturing with IDT Australia Additional Indications* Peter Mac Peter MacCallum Cancer Centre Victoria Australia against multiple cancers Australian patent granted covering INV043 Phase 1 clinical trials Pre-clinical for new API INV043 / Portfolio of new compounds 2013 ... 2017 2021 2023 2024 2025 idt australia Additional Indications* Phase 1b/2 clinical trials *Indicative timelines >2025 INVION#6THE PHOTOSOFT™M ADVANTAGE A NOVEL CANCER TREATMENT 5 & NGPDT (Next-Gen PDT) is a ground-breaking technology that overcomes many of the shortcomings of early PDT technologies and aims to transform the treatment of a wide range of cancers NGPDT is a minimally invasive modality for treating cancer that specifically identifies and destroys cancer cells whilst leaving the rest of the body's normal cells unharmed Photodynamic Therapy (PDT) consists of three elements: Combines photosensitiser 1 compound with light- 2 Generates reactive oxygen species ("ROS") causing damage to only 3 induced activation targeted cells Light Direct cell death along with activation of immune response Necrosis Photosensitiser Cellular Generation of accumulation in→ tumour tissue localisation reactive 02 Cellular damage Cell death via Apoptosis 01 02 2 03 50 04 05 Autophagy INVION#7LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS ATTRACTIVE THERAPEUTIC PROFILE 6 Preclinical studies in lead cancer candidate INV043 show: Effective in regressing multiple types of cancer in vivo -600x greater photoxicity than Talaporfin (widely used photosensitiser) Selectively absorbed by cancer cells and not healthy tissue INV043 activity against multiple cancer cell types4 100 80- 60 Viability (% of control) 00 40 20- Ovarian (SKOV3) Colorectal (DLD1) Liver (HEK293) T-cell Lymphoma (HH). → Lung (A549) Triple Negative Breast (MDA-MB-468) Stimulate the body's natural immune response AI Work additively with blockbuster ICI¹ drugs Non-toxic, safe and limited side effects at up to 100x therapeutic dose Supporting translation into successful clinical trials² 1 Immune Checkpoint Inhibitor (ICI) therapies are part of the Immunotherapy market 2 Human Ethics submission for first NMSC clinical trial by end of CY2023 4 Studies carried out by Hudson Institute 0.001 0.01 0.1 1 Photosensitizer (μM) INV043 fluorescing in a tumour under light4 INVION#87 POTENTIAL TO ACTIVATE AN IMMUNE RESPONSE PROTECTIVE IMMUNITY AND ABSCOPAL EFFECT "PDT has the potential to eliminate metastatic and disseminated tumor cells by promoting antitumor immunity"1 ABSCOPAL EFFECT2 NON-IRRADIATED SIDE Rt. tumor volume mm³ • Control ■ Abs eff * Absineff 800 400 0 IRRADIATED SIDE After 18 days NON-IRRADIATED SIDE Abs eff and AbSineff groups separated based on the tumor-specific efficacy of PDT and abscopal effect 800 8 12 16 Days post inoculation 400 16 Days post inoculation IRRADIATED SIDE Treated Control PROTECTIVE IMMUNITY Pre- Endpoint treatment https://inviongroup.com/videos-reports/ A 2023 PDT study published in Nature¹ • Demonstrated abscopal effect in melanoma and pancreatic cancer models by inducing T cell activation and antitumor immunity through PD-1/PD-L1 blockade Elicited the inhibition of tumour growth Improved abscopal effect by enhancing T cell infiltration and inhibiting PD-1/PD-L1 interactions "Substantial regression in tumour size observed at both right (irradiated) and left (non-irradiated) site"¹ • • Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies Proof of Concept (POC) pilot showed complete regression of TNBC in vivo following INV043 treatment Tumour mass undetectable two weeks after initial treatment and no scarring evident No recurrence of disease, re-challenge with TNBC implant could not re-establish new tumours, suggesting development of protective immunity 1 Adapted from https://www.nature.com/articles/s41598-023-30256-0 #citeas, using chlorin e6 photosensitizer. 2Abscopal Effect: When the treatment not only shrinks the targeted tumour but also untreated tumours elsewhere in the body. INVION#9COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL 8 • • . Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as 12.5%¹ Independent in vivo studies showed combined INV043 and anti-PD-1 therapies achieved 80% tumour elimination HUDSON INSTITUTE:. ~65% REDUCTION IN TUMOUR VOLUME (TRIPLE NEGATIVE BREAST CANCER, INTRATUMORAL)² 4T1 breast tumours treated using a restricted INV043 PDT protocol (intratumoural) and / or anti PD-1 antibody (intratumoral) Monotherapies restricted tumour growth vs untreated controls Combination therapy regressed and stabilized tumours and achieved a ~65% reduction in tumour size at endpoint (n=4/group) Tumour volume (mm²) 150- 100 50- PDT #1 10 PDT #2 20 T 30 40 Days post tumour-inoculation INV043 control IgG2a control + anti-PD-1 alone ⚫ PDT (restricted) combination Combi therapy: -65% increase in effectiveness vs. ICI alone PETER MAC: -80% RESPONSE RATE (ANAL SCC CANCER, TOPICAL)³ Anal Squamous Cell Carcinoma (ASCC) tumours treated using a restricted INV043 PDT protocol (topical) and / or anti PD-1 antibody Monotherapies restricted tumour growth vs untreated controls, with standalone INV043 showing lower tumour volume vs ICI alone Combination therapy resulted in 80% tumour-free subjective at endpoint (n=8-10/group) %Tumor free 100 80- 60- 40 20- 0 10 20 20 *** INV043+PD1 vs Vehicle = p=0.001 ** INV043+PD1 vs PD1 p=0.0037 * INV043 vs Vehicle p=0.0397 30 40 Days 1 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2762389 2 https://announcements.asx.com.au/asxpdf/20220530/pdf/459ffkjbvdpjrg.pdf 3 Per ASX announcement 4 March 2024 - 7/10, no measurable tumour. 8th mouse histology, no evidence of tumour cells 50 INVO43 PD-1 60 60 INVO43 Isotype Control Vehicle PD-1 Vehicle Isotype Control ** *******#10TREATMENT OPTIONS: MAXIMISING FLEXIBILITY FOR CLINICIANS MULTIPLE PATHWAYS FOR DRUG AND TARGETED LIGHT DELIVERY 9 ROUTES OF DRUG ADMINISTRATION LIGHT ADMINISTRATION OPTIONS TOPICAL INTRAVENOUS TOPICALLY (LASER/LED) ENDOSCOPICALLY INTRATUMORAL SUBLINGUAL WITH OPEN SURGERY Esophagogastroduodenoscopy (EGD or upper endoscopy) Esophagus Endoscope Light Stomach KEYHOLE SURGERY INVION#11TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS, MULTIPLE INDICATIONS AND FORMULATIONS 10 DISEASE AREA (CALENDAR YEAR) 2H2023 1H2024 2H2024 1H2025 2H2025 >CY26 CANCER1 Non-Melanoma Skin Cancers (Topical)² Solid Tumour Cancer Indication (IV): (TBC) Anogenital Cancers (Topical) Additional Indications: International (TBC) NEXT CLINICAL TARGET INFECTIOUS DISEASES Oral Microbial (Peri-Implant Mucositis)³ HPV (Dr.inB) Discovery PreClinical Recruitment and Treatment Adaptive study design Follow up and monitoring Phase 1 Phase 1b/2 1 RMW Cho Group ("RMW") as licensor of PhotosoftTM technology, is pursuing independent research in parallel with Invion's R&D efforts including a prostate cancer trial. The research is complementary/supplemental to Invion's development program. To the extent that Invion becomes aware of material information relating to RMW's studies, Invion will release the information to the ASX in compliance with its disclosure obligations (noting however that Invion is not involved in RMW's studies and does not have direct access to information) 2 NMSC trial uses an adaptive study design means recruitment numbers and timelines may change to accelerate the evaluation of INV043 3 Timing subject to ongoing dialog with US FDA to determine pre-clinical requirements INVION#12EVALUATING NMSC THERAPIES¹ IVX-PDT - POTENTIAL TO DISPLACE STANDARD OF CARE GOOD COSMETIC RESULT 11 POOR FAIR Metvix/ALA Cryosurgery IVX-PDT Curettage & Electrodesiccation Mohs Surgery Excisional Surgery EFFECTIVENESS GOOD Based on management views 1 https://www.aad.org/news/guidelines-to-treat-nonmelanoma-skin-cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746716/ Less Pain/ Discomfort Skin (NMSC) More Pain/ Discomfort) INVION#13UNLOCKING HOPE FOR CANCER PATIENTS USING PDT ADDRESSING LIMITATIONS OF CONVENTIONAL TREATMENT OPTIONS 12 A Minimally Invasive treatment option that preserves both function and aesthetics No Resistance Development, allowing for repeated treatments on recurring tumors without compromise Selective Targeting preserves healthy organ tissues, thus minimizing collateral damage + Potential Adjunctive Treatment, PDT seamlessly integrates with other therapies for enhanced effectiveness INVION#1413 BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL POSSIBILITY FOR SEVERAL ANTIMICROBIAL TREATMENTS – WITHOUT RESISTANCE - “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity" Leading Institutions: Viroclinics conducted virus tests & ACARE (University of Adelaide) conducted bacteria and fungi tests World Health Organisation' SARS-COV-2: Omicron Selected Photosoft™ Compounds vs. Remdesivir Broad Spectrum Potential: In vitro tests showed Photosoft™ to be effective against several types of pathogens, including antibiotic-resistant superbugs Need for New Treatment Options: Potential for PhotosoftTM as a new treatment class for polymicrobial infections and/or where pathogens cannot develop drug resistance Given the general mode of action of PDT... it is unlikely for superbugs to develop resistance to the compounds Prof Darren J. Trott, Director, Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide 1 https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance " % Inhibition 100 80 PhotosoftTM compounds 60 40 20 Remdesivir 0 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 Concentration μM 0.9 1 им 30 25 20 15 10 5 Broad Spectrum Activity: Minimum Inhibition Concentration (MIC50) of Selected Photosoft Compound following exposure to light for 5 minutes#15AGREEMENT TO DEVELOP AND FUND PHOTOSOFT™ FOR HPV HPV IS THE MOST COMMON SEXUALLY TRANSMITTED INFECTION GLOBALLY¹ In all females, the highest (HPV) prevalence is found in Asian regions² HPV distribution profile in women² CHALLENGES IN TREATMENT Viral persistence and recurrence Limited effectiveness of current treatments topical medications, surgical and ablative therapies 57.7% 44.4% 42.2% 21.4% 3.7% Eastern Asia Central & Sub-Saharan Southern Asia Africa Eastern Europe Western Europe • Leads to anogenital and oropharyngeal cancers • Limited access and high cost of HPV vaccination Vaccine hesitancy 14 • DR.INB TO DEVELOP AND FUND PHOTOSOFT FOR THE TREATMENT OF HPV Undertake and fund evaluation plus in-human Proof-of-Concept clinical trials to test patient safety and efficacy ⚫ Dr.inB is a leading developer of PDT treatments in South Korea backed by Hanlim Pharma. Co., Ltd. • Collaboration provides accelerated pathway to demonstrate clinical potential of Photosoft in infectious diseases like HPV . Invion retains all rights to Photosoft and any new IP from the collaboration https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer 2 https://www.sciencedirect.com/science/article/abs/pii/S0264410X12010808 INVION#16ADDRESSING ASIAN-CENTRIC DISEASES ADDRESSING A GLOBALLY RELEVANT UNMET NEED 15 Asians comprise 6% of clinical trial patients in FDA approved drugs² ... yet 60% of the world is Asian UNDER-REPRESENTATION IN DRUG DEVELOPMENT Ethnic Breakdown of Clinical Trials for 2020 Approved Drugs² 11% Hispanic 8% Black 6% Asian MISMATCH WITH GLOBAL INCIDENCE Nasopharyngeal Cancer 86.0% cases in Asia, esp. China, HK Oral Cancer 65.8%¹ cases in Asia esp. India, Indonesia, Pakistan Stomach Cancer 75.3% cases in Asia, esp. Korea, Japan and China Oesophageal Cancer 79.7% cases in Asia esp. in east Asians 75% White Liver Cancer 72.5% cases in Asia mainly in China Non-Smoker Lung Cancer 60-80% women in Asia with lung cancer are non-smokers (esp. China). Highest among Asian American females in US4 Thfps://gco.jarc.fr/today/fact-sheets-cancers. GLOBOCON 2020 2 Source: Food and Drug Administration - 2020 Drug Trials Snapshots Summary 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431055/#b12-ms117_p0375 4 https://med.stanford.edu/content/dam/sm/care/communityheathtalk/Stanford-Community-Health-Talk-LCINF- FANS-2-21-2022.pdf INVION#17Stanford Center for Asian Health Research and Education (CARE) . Only medical center among top universities in the US dedicated to enhancing the precision health of Asians globally Rooted in Stanford Medicine's pioneering precision health approach, we are committed to targeted prediction, prevention, and curing of diseases By addressing Asian health disparities and advancing precision health for Asian populations worldwide, CARE aims to revolutionize health outcomes Our Mission To elevate understanding, enable research / education, and positively impact clinical care to transform Asian health in patients, providers and the community Stanford Center for Asian Health MEDICINE Research and Education#18Platform Infrastructure Pillars Vision CARE Precision Asian Health Framework Academic Leader in Precision Asian Health Research Education Community Asian Health Research and Education Platform Summit/Conference Management Research / Education Grant Support Public Policy Initiatives Program Management Automated Impact Tracking Marketing Comm's/Media/Web/Events Sustained, Predictable Funding Stanford Center for Asian Health MEDICINE Research and Education#19INVION TM#20APPENDICES#2120 20 TUMOUR REGRESSION IN VIVO SIGNIFICANT REGRESSION ON MULTIPLE TUMOUR TYPES • • . INV043 was used to treat implanted T-cell lymphoma, breast and pancreatic cancers in vivo Low dose (0.1 mg/kg) administered by intra-tumoral injection and laser light applied after 1.5 hours. Treated twice over a 24 hour period. Control animals received either laser or INV043 alone. Tumours measured for 1 week following treatment to assess change in tumour size Significant tumour regression was achieved in all cases A. T-cell Lymphoma 600] % tumour size change 400 200 5001 400- 300- 200- 100 % tumour size change 0 2 み 6 days post-treatment - Treated - Control Triple Negative Breast Cancer 0 2 4 days post-treatment B. % tumour size change T-cell Lymphoma - Treated - Control Breast Cancer Pancreatic 6 8 Cancer Pancreatic cancer 1500 1000 500 - Treated - Control 0 2 4 6 8 days post-treatment Pre-treatment Day 0 Day 2 Day 4 Day 6 Control Pre-treatment Day 0 Day 2 Day 4 Day 6 Control (A) All tumour types regressed following treatment, as determined by decrease in measurable volume. Significant reduction in tumour volume was recorded for all treated mice relative to untreated controls (B) Immediately following laser activation tumour tissue became less palpable and developed a "bruised" appearance. Necrosis of tumour evident within 2 days as a distinct darkening of tumour mass beneath the skin. Followed by formation of a visible eschar in all cases after 2-4 days. Neither laser nor INV043 alone had any measurable effect (n=4-8/group) INVION Pre-treatment Day 0 Day 2 Day 4 Day 6 Control#22. PETER MAC COMBINATION ICI AND INV043 STUDY STUDY DESIGN The study was conducted by Peter Mac using immune competent anal squamous cell carcinoma (ASCC) in vivo models INV043 was topically applied to 6-8 week old C57BL/6 mice followed 3 hours later with 71 J/cm2 of 660nm light on Day 0 and Day 3. On Days 2, 6, 10 and 14 PD-1 was administered by intraosseous infusion as per the below schematic diagram ⚫ Peter Mac generated an anal SCC line using a transgenic mouse model (CE cell line) Four groups: Combination INV043 + Anti-PD-1, INV043 alone, Anti-PD-1 alone, control (n=8-10/group) 5x106 mouse SCC cells (sub cut injection) 3hr + Light INV043 topical 3hr + Light 10 #1ip INV043 topical 21 10 #2ip Day 6 10 #3ip Day 10 10 #4ip Day 14 Day 60 Day 0 Day 1 Day 2 Day 3 Day 4 Tumour size 200mm³ Tumour growth measurement/ health monitoring 6-8 weeks old C57BL/6 Experimental endpoint: Day 60 post treatment or humane endpoint: until tumour size ≥1500mm³ INVION#23PETER MAC COMBINATION ICI AND INV043 STUDY FINDINGS AND IMPLICATIONS . • Combination therapy using INV043 with ICIs led to -80% control of ASCC tumours at study endpoint, compared with ICI therapy alone, which achieved -12% control. Results were statistically significant Mice under combination treatment maintained healthy weight with no negative side effects noted Opens additional treatment options for upcoming clinical trial programs that span multiple cancers ASCC has potential for orphan designation - leading to an expedited regulatory approval process Findings reinforce potential for collaboration partnerships using combination therapies to extend the patent life of blockbuster ICIs • AVERAGE TUMOUR VOLUMES SUBSTANTIALLY LOWER IN COMBINATION TREATMENT GROUP Average tumour volume post treatment 2000- STANDALONE INV043 EXHIBITED LOWER TUMOUR VOLUMES THAN STANDALONE ICIS Tumour Volume (mm³) 2000 1500- 1000 500- INV043 and PD-1 showed significant decrease in average tumour size Tumour Volume (mm³) 1500- 1000- 500- FFFF 1 7 INVO43 PD-1 INVO43 ― Vehicle _ Isotype Control PD-1 Vehicle Isotype Control 13 19 25 31 37 43 49 60 Days post 1st treatment PD-1 alone reached ethical endpoint (tumours >1500mm) except one where tumour was controlled 3 7 11 15 INVO43 ✰ Vehicle 19 23 27 31 35 39 43 47 51 60 Day post 1st treatment Isotype Control (1/8) PD-1 (1/8) INVION#24NON-MELANOMA SKIN CANCER (NMSC) THE WORLD'S MOST COMMON CANCER : SKIN CANCER4 23 23 Australia: Highest skin cancer incidence globally2 SCC -19% Melanoma -1% NMSC: Incidence rates (2020)2 per 100,000 Epidermis Others -1% Dermis 150 114.9 100 64.4 Hypodermis Muscle layer 50 16 BCC -79% 1.5 0 Australia &... USA & Canada Europe Asia Non-Melanoma Skin Cancer¹ 5-Yr Prevalence Worldwide 6.5M2 BCC: Basal Cell Carcinoma | SCC: Squamous ell Carcinoma | MCC: Merkel Cell Carcinoma EPIDEMIOLOGY AND RISK FACTORS³ BASAL-CELL CARCINOMA Basl cell Skin (NMSC) Basement membrane Melanocyte Basal cell carcinoma SQUAMOUS-CELL CARCINOMA Ulcer Hard raised edges. Dead keratinocyte Keratinocyte Cancer cell Stratum corneum Epidermis Dermis Hypodermis Muscle layer • • Major factor: UV-rays exposure Genetics: Family history of skin cancer Skin pigmentation: Fair-skinned > Dark-skinned • Age: Older individuals • Gender: Men > Women Association: Human Papilloma Virus, certain chemicals UNMET MEDICAL NEEDS Standard treatment option: Surgery, often leads to scarring and pain Inconsistent treatment outcomes Side effect management (radiotherapy, brachytherapy, chemotherapy) Need for more effective and less invasive treatment options for advanced cases https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/introduction 2 Source GLOBOCON 2020, WHO 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432795/ 4 https://amp.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html INVION#25PHASE 1/2 NON-MELANOMA SKIN CANCER TRIAL DESIGN1 ADAPTIVE DESIGN: SAFETY AND TOLERABILITY, DOSE OPTIMISATION, EFFICACY • Increased Optionality: Open label adaptive trial design (3+3 light dose / dose light interval escalation²) enables flexibility in size and timing, with option for repeat treatment depending on response ⚫ Ahead of the Curve: Earlier parts focus more on safety and tolerability, later parts more on dose and schedule optimization, and efficacy • Significant Cancer Market: Cutaneous Squamous Cell Carcinoma (cSCC) and superficial Basal Cell Carcinoma (SBCC) ENDPOINTS Part 1 Light Dose, 3+3 Dose-Escalation* Part 2 Part 3 Dose Expansion*** ■ Safety and tolerability including Dose Limiting toxicity (DLT) ■ Dose Light Interval Optimisation Light dose, dose light interval investigations ■ (Optional**) Anti-tumour activity ■ Pharmacodynamic investigations (exploratory) INV043 dose is fixed at 0.5% w/w ointment for dermal application. Wavelength: 660 nm; Intensity: 100 mW/cm² * ** If suboptimal clinical activity is noted in Part 1, the Safety Review Committee (SRC) may decide to open enrolment in Part 2 to optimise the DLI for PDT with INV043 at any light dose level that has been deemed to be safe by the SRC Following completion of at least 1 cohort in Part 2, SRC may decide to return to escalate the light dose and re-open Part 1 light dose escalation *** Part 3 of study will investigate the anti-tumour activity of PDT, further assess the safety and tolerability of INV043 given at the recommended doses for future exploration of the light dose and DLI determined in Part 1 and (if applicable) the DLI in Part 2 1 Subject to Human Research Ethics Committee (HREC) approval 2 In a "3+3 design," three patients are initially enrolled into a given dose cohort. If there is no DLT (dose limiting toxicity) observed in any of these subjects, the trial proceeds to enroll additional subjects into the next higher dose cohort. INVION#26ORAL PERIODONTAL DISEASES 19% OF GLOBAL ADULTS SUFFER FROM SEVERE PERIODONTAL DISEASES¹ Oral periodontal diseases are one of the major public health challenge in South-East Asia - WHO5 Increase in Prevalence over decades² 25 540,000,000 1,087,000,000 NUMBER OF CASES 1990 2019 RISK FACTORS³ Dietary factors: High Sugar, low-fibre diet Association: Diabetes, osteoporosis, plaque, smoking, tobacco • Genetics Age: Mostly older population Healthy Gums Plaque & Tartar Buildup Healthy Bone Level Pocket Unhealthy Gums Reduced Bone Level "20% of Implant patients suffer from peri- implantitis, which if left. untreated leads to implant loss."6 • CHALLENGES IN CURRENT TREATMENTS4 Need for accessibility to deep pockets without surgery Post-operative complications after surgery • Recurrence • Resistance development to antibiotics Side effects of antibiotic therapy, local inflammation Patient compliance https://www.who.int/news-room/fact-sheets/detail/oral-healthhttps://www.who.int/news-room/fact-sheets/detail/oral-health 2 https://onlinelibrary.wiley.com/doi/epdf/10.1111/odi.14436 3 https://www.perio.org/for-patients/gum-disease-information/gum-disease-risk-factors/v4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216136/ 4 Carranza's Clinical Periodontology- Tenth Edition 5 https://www.who.int/publications/i/item/9789290210061 6 https://pubmed.ncbi.nlm.nih.gov/28478213/ INVION#27INVION DENTAL KIT1 POTENTIAL TO ADDRESS PERIODONTAL NEEDS, EFFICIENT PATH US FDA APPROVAL 26 26 INVION DENTAL RINSE What Periodontists are looking for INVION DENTAL DEVICE Mouthpiece Powerpack Controller Alternatives to antibiotic therapy ➤ Tackling the menace of biofilms ➤ Non-surgical access to deep pockets ➤ Comfortable and effective treatment options for patients ➤ Ensuring longevity of costly tooth implants 1 Concept application for illustration purposes only, may be amended based on further developments and subject to FDA review INVION#28MARKET OVERVIEW $0.005 (@ 28 February 2024) Market Cap A$32.1m $0.008 $0.007 $0.006 $0.005 Focus Clinical-stage life sciences company developing the PhotosoftTM technology as a treatment for a range of diseases including cancers Issued Shares Cash (@ 31 December 2023) Revenue (Year ended 30 June 2023) Symbol/ Exchange 1-Year Price and Volume Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 Feb Source: Market Index Top 10 Shareholders % POLAR VENTURES LIMITED 8.49 6.4 B BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT DRP> RMW CHO HEALTH TECHNOLOGY LIMITED RMWC PTY LTD <RMWC FAMILY A/C> 8.33 5.01 4.90 MR HONSUE CHO 4.43 AUD $1.9M NGPDT GREATER CHINA LIMITED 4.25 MEI JUN LIN 4.24 $4.1M ACSLNC PTY LTD <ACSLNC FAMILY A/C> 3.50 CITICORP NOMINEES PTY LIMITED 2.53 SUREFIT CAPITAL PTY LTD 2.34 ASX: IVX TOTAL 48.02 27 27 Next Generation Photodynamic Therapy | March 2024 INVION#29EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS 28 THIAN CHEW EXECUTIVE CHAIRMAN & CEO • Co-Founder, Chronic Airway Therapeutics Advisory Board, Stanford Medicine CARE • Executive Director, Goldman Sachs • Director, KPMG Consulting, Senior Manager KPMG . Adj. Prof. HKUST, MBA/MA Wharton School SCOTT CARPENTER PROGRAM DIRECTOR Director Business Development, Starpharma Program Manager, AusBiotech Regulatory Affairs, Bayer CropScience • MBA Melb Business School, B. Applied Science RMIT DR AMY PRAWIRA MEDICAL CONSULTANT • • . • Founder/CEO, Obatica Pty Ltd (engaged to assist with clinical trials) 12+ years in clinical oncology and trials Investigator with experience in over 90 early phase clinical trials Head, Cancer Trials and Research Unit, Prince of Wales Hospital (Sydney) KIM STEEL CLINICAL TRIAL MANAGEMENT • • 18+ years managing global and clinical drug and device studies from Phase 1-IV across 14 countries Managing Director, SAPRO Consulting . Project Director, Novotech Project Manager, Pacific Clinical Research Group ALEXANDER BENNETT TECHNICAL ADVISOR, LIGHT DEVICES . 35+ years in R&D, manufacturing and commercialisation of scientific instrumentation incl. ISO certifications • GM Forensic Light Sources, Rofin Australia. • Led Medical Light Source trial for PDT in skin cancers Peter MacCallum Cancer Centre NICOLETTA MUNER REGULATORY AND CLINICAL DEVELOPMENT . • 20+ years non-clinical and clinical drug development, quality, manufacturing, incl. EMA and US FDA approval Founder Canary Regulatory Affairs Global Regulatory Affairs, Clinuvel Pharmaceuticals • Pre-clinical and regulatory affairs, Pfizer DR SEBASTIAN MARCUCCIO MEDICINAL CHEMISTRY • • • 35+ years in pharmaceutical/organic chemistry drug discovery and development (co-inventor recent PDT patents) Founder/Director Advanced Molecular Technologies Previously in Pharmaceutical Chemicals Research, CSIRO Adj. Prof. La Trobe University, PhD Organic Chemistry ANU LOUISE WHITE MANUFACTURING AND QUALITY • • 35+ years in the pharmaceutical industry, 13 years in vaccine manufacturing, CSL, Partner SeerPharma Experience in virology R&D, bacterial vaccines production, quality control and production planning . Registered auditor for APVMA INVION